

Palliative Thyroid Cancer Regimens

The following table lists the evidence-informed regimens (both IV and non-IV) for thyroid cancer used in the palliative setting. It is expected that the prescribing oncologist will select the regimen from the list of evidence-informed regimens that is most appropriate for their patient taking account of a variety of disease-specific and patient-related factors.

Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.

Thyroid Cancer	
Regimen Code	Regimen Abstract
DOXO	DOXOrubicin 50-60 mg/m ² IV day 1. Q21 days
LENV	Lenvatinib 24 mg PO daily
PACL(W)	PACLitaxel 80 mg/m ² IV days 1, 8, 15. Q28 days
SORA	SORafenib 400 mg PO BID – Not currently publicly funded for this regimen and intent
VAND	VanDETanib 300 mg PO daily – Not currently publicly funded for this regimen and intent

Last Updated: November 2017